ImmunoGen maps new path to accelerated approval; BioNTech scores €50M funding from European bank
→ Earlier this year, struggling ImmunoGen was shooed away by the FDA with their case for an accelerated approval of their antibody-drug conjugate …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
